Benign Prostatic Hyperplasia Clinical Trial Pipeline Highlights 2019 – Global Forecast to 2024 by Clinical Trial Stage, Drug Mechanism Class, Company – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Benign Prostatic Hyperplasia Clinical Trial Pipeline Highlights – 2019”
report has been added to ResearchAndMarkets.com’s
offering.

Benign Prostatic Hyperplasia Pipeline Highlights – 2019, provides most
up-to-date information on key pipeline products in the global Benign
Prostatic Hyperplasia market. It covers emerging therapies for Benign
Prostatic Hyperplasia in active clinical development stages including
early and late stage clinical trials. The pipeline data presented in
this report helps executives for tracking competition, identifying
partners, evaluating opportunities, formulating business development
strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Benign Prostatic Hyperplasia pipeline products by
clinical trial stages including both early and late stage development –
phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical
trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Benign Prostatic Hyperplasia pipeline products by
their dominant mechanism of action/drug class. This helps executives
categorize products based on their drug class and also assess the
strengths and weaknesses of compounds.

Company:

The report provides Benign Prostatic Hyperplasia pipeline products by
the company.

Short-term Launch Highlights:

Find out which Benign Prostatic Hyperplasia pipeline products will be
launched in the US and Ex-US till 2024.

Key Topics Covered:

1. Benign Prostatic Hyperplasia Pipeline by Stages

2. Benign Prostatic Hyperplasia Phase 3 Clinical Trial Insights

3. Benign Prostatic Hyperplasia Phase 2 Clinical Trial Insights

4. Benign Prostatic Hyperplasia Phase 1 Clinical Trial Insights

5. Benign Prostatic Hyperplasia Preclinical Research Insights

6. Benign Prostatic Hyperplasia Discovery Stage Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/yldwxr

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Prostate
Cancer Drugs, Clinical
Trials